Sidoti Predicts Kamada’s Q3 Earnings (NASDAQ:KMDA)

Kamada Ltd. (NASDAQ:KMDA) – Equities research analysts at Sidoti dropped their Q3 2026 earnings estimates for Kamada in a report issued on Friday, September 25th. Sidoti analyst J. Sidoti now anticipates that the biotechnology company will post earnings of $0.10 per share for the quarter, down from their previous estimate of $0.12. The consensus estimate for Kamada’s current full-year earnings is $0.49 per share. Sidoti also issued estimates for Kamada’s Q4 2026 earnings at $0.09 EPS, Q1 2027 earnings at $0.10 EPS, Q2 2027 earnings at $0.11 EPS, Q3 2027 earnings at $0.13 EPS, Q4 2027 earnings at $0.12 EPS, Q1 2028 earnings at $0.11 EPS, Q2 2028 earnings at $0.12 EPS and FY2028 earnings at $0.50 EPS.

A number of other equities analysts have also weighed in on KMDA. Benchmark reaffirmed a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. UBS Group reissued a “buy” rating and issued a $15.00 price target on shares of Kamada in a research report on Friday, September 18th. Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a research note on Tuesday, September 22nd. William Blair set a $15.00 price target on shares of Kamada in a research note on Tuesday, July 21st. Finally, Wall Street Zen upgraded shares of Kamada from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $13.50.

Kamada Stock Performance

KMDA stock opened at $8.62 on Monday. The stock’s 50 day simple moving average is $7.90 and its 200 day simple moving average is $7.89. Kamada has a fifty-two week low of $6.50 and a fifty-two week high of $9.35. The company has a market cap of $495.74 million, a P/E ratio of 22.68, a price-to-earnings-growth ratio of 0.71 and a beta of 0.88.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.05. The firm had revenue of $54.92 million for the quarter, compared to analyst estimates of $50.84 million. Kamada had a net margin of 11.60% and a return on equity of 8.37%.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Kamada stock. Aristides Capital LLC increased its stake in shares of Kamada Ltd. (NASDAQ:KMDA) by 4.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,491 shares of the biotechnology company’s stock after buying an additional 1,476 shares during the quarter. Aristides Capital LLC owned 0.06% of Kamada worth $288,000 at the end of the most recent quarter. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Kamada Cuts Dividend

The business also recently disclosed an annual dividend, which was paid on Thursday, September 17th. Stockholders of record on Thursday, August 27th were paid a $0.17 dividend. This represents a dividend yield of 206.0%. This is a drop from Kamada’s previous annual dividend of $0.25. The ex-dividend date of this dividend was Thursday, August 27th. Kamada’s dividend payout ratio (DPR) is currently 34.21%.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company focused on the development, manufacture and commercialization of plasma-derived and specialty pharmaceutical products. The company’s portfolio is aimed primarily at treating rare diseases and other conditions requiring replacement or immune-modulating therapies.

Kamada’s principal product is GLASSIA, an intravenous alpha-1 proteinase inhibitor used as augmentation therapy in adults with alpha-1 antitrypsin deficiency, a rare genetic disorder that can cause progressive lung disease.